Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Bioxyne Limited ( (AU:BXN) ) has provided an announcement.
Bioxyne Limited has announced its FY2026 revenue guidance of $65-75 million and EBITDA guidance of $11.5-13.5 million, driven by growth in its Australian medical cannabis business and international expansion. The company has secured new contracts with large distributors and clinics, including a significant contract in Germany, marking its entry into high-growth markets in the UK, Germany, and other EU countries. This expansion is expected to significantly enhance Bioxyne’s market positioning and contribute to its growth in the coming year.
More about Bioxyne Limited
Bioxyne Limited is an Australian pharmaceutical and healthcare company focused on manufacturing and distributing novel medicines, health products, and active pharmaceutical ingredients, including medicinal cannabis, MDMA, and Psilocybin. Its subsidiary, Breathe Life Sciences, specializes in alternative therapeutics and investigational medicines, operating internationally with facilities in Australia, Japan, the UK, and Czechia.
Average Trading Volume: 5,116,791
Technical Sentiment Signal: Buy
Current Market Cap: A$126M
Find detailed analytics on BXN stock on TipRanks’ Stock Analysis page.